An observational study in Chronic Pain, Depression Disorders and Anxiety Disorders, sponsored by Santa Catarina Federal University. Enrolling by invitation at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-30.
Sponsored by Santa Catarina Federal University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Chronic Pain with a site in Brazil — 10 open to participants now, 12 under way, none of them phase 3. Chronic Pain · Brazil.
Among the 67 studies in Chronic Pain with a site in Brazil, this one is one of 2 that started in 2026, is one of 5 observational ones, reaches primary completion later than 7 of the 11 other live ones, and was the 63rd registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →10 of the 67 studies in Chronic Pain with a site in Brazil are open now. Recruiting first, the newest first:
Universidade Federal do Rio Grande do Norte · Sites in Brazil
Ages 18–65 · Women only
Federal University of Bahia · Sites in Brazil
Ages 18–55
Universidade Federal do Rio Grande do Norte · Sites in Brazil
Ages 20–69
University of Sao Paulo General Hospital · Sites in Brazil
Ages 18+
University of Nove de Julho · Sites in Brazil
Ages 18–50
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 384 is above the median of 120 across 755 observational studies indexed under Chronic Pain.
Median enrollment 60 across the 61 interventional studies, 308 across the 5 observational. Of the 37 that completed or were terminated, 3 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 67 have an industry lead sponsor. The 10 most frequent:
Santa Catarina Federal University is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Santa Catarina Federal University has 1 study filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
1 of the studies in Chronic Pain with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07783295Associação Pan-Americana Multidisciplinar de EndocanabinologiaFull-Spectrum Cannabis Extract for Chronic Pain and Bone Health Biomarkers in Women | 2027-09-01 |
Add it to your calendar (.ics) → With an account.
Among the 67 studies in Chronic Pain with a site in Brazil, from their registry updates:
This tab as a report to print or save as PDF → With an account.
What is the purpose of this study? The use of medicinal cannabis has grown significantly in Brazil. However, because many patients use these products through "compassionate use" (when traditional treatments haven't worked), there is still a lack of large-scale data on how these treatments perform in daily life. This study, called CANAREAL, aims to track patients across Brazil to understand if cannabis-based products are truly effective and safe for treating various conditions, such as chronic pain, anxiety, and depression.
How will the study work? This is an observational study, which means the researchers will not provide the medication or change the treatment prescribed by the patient's doctor. Instead, we will simply "follow" the patient's journey for 6 months.
What will participants be asked to do? Participants will complete online questionnaires at different stages of their treatment. These tools will measure:
Quality of Life: How the treatment affects daily well-being.
Clinical Evolution: Changes in pain levels, anxiety, and depression symptoms.
Safety: Whether the patient experiences any side effects (adverse events).
Why is this study important? Unlike controlled laboratory tests, this "Real-World Study" captures the reality of diverse patients with different backgrounds and health needs. The information gathered will help doctors, patients, and health authorities in Brazil better understand the benefits and risks of cannabinoid therapy, leading to safer and more informed medical decisions in the future.
Study Rationale and Context The CANAREAL study is designed as a prospective, longitudinal, observational investigation aimed at filling the gap between controlled clinical trials and the clinical reality of medicinal cannabis use in Brazil. Under current Brazilian regulations (RDC 327/2019 and RDC 660/2022), patients access cannabinoid-based products primarily through compassionate use. This study adopts a Real-World Evidence (RWE) approach to evaluate how these treatments perform across a heterogeneous population with various comorbidities and treatment regimens.
Study Design and Procedures Participants who have already been prescribed cannabis-based products by their physicians will be recruited. The study does not interfere with medical prescriptions, dosages, or product choices.
Data collection will be conducted at three specific time points over a 180-day (6-month) period:
Baseline (T0): Collection of demographic data, medical history, primary reason for cannabis use, and previous conventional treatments. Initial scores for pain, anxiety, depression, and quality of life will be recorded.
Intermediate Follow-up (T1 - 90 days): Assessment of clinical evolution and monitoring of any early adverse events.
Final Assessment (T2 - 180 days): Final evaluation of therapeutic efficacy and overall impact on the patient's quality of life.
Instruments and Measurements To ensure objective quantification of subjective symptoms, the following validated psychometric and clinical tools will be utilized:
Quality of Life: The WHOQOL-Bref (World Health Organization Quality of Life) and EUROQOL-5D scales.
Clinical Symptomatology: The Visual Analogue Scale (VAS) for pain intensity, the Beck Depression Inventory (BDI), and the Beck Anxiety Inventory (BAI).
Safety Profile: The UKU Side Effect Rating Scale will be used to document the frequency, severity, and nature of adverse drug reactions (ADRs).
Data Management and Analysis Data will be collected via secure digital platforms (Google Forms/WhatsApp). Statistical analysis will include descriptive statistics for demographic characterization and inferential analysis (e.g., paired t-tests or non-parametric equivalents) to compare baseline scores against the 3-month and 6-month follow-ups. The study intends to identify patterns of efficacy based on the cannabinoid profile (CBD-dominant, THC-dominant, or balanced) and the specific medical conditions treated.
Ethical Compliance The study is conducted in accordance with the Declaration of Helsinki and submitted for approval by the Research Ethics Committee of the Federal University of Santa Catarina (CEP/UFSC). All participants must provide electronic Informed Consent (ICF) before data collection begins.
The study targets a diverse population of patients in Brazil who seek cannabinoid therapy for various medical conditions, primarily chronic pain, anxiety, and depression, through the pharmaceutical and clinical service flow of partner companies and clinics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who use or are starting treatment with cannabis-based products prescribed under Brazilian regulations (RDC 660/22). This group includes individuals seeking treatment for various clinical conditions, such as chronic pain, anxiety, and depression, through compassionate use.
Dietary Supplement: Participants are followed while using cannabis-based products (such as CBD or THC oils, extracts, or isolates) as prescribed by their own physicians for therapeutic purposes.
This is an observational study of patients using cannabis-based products as prescribed by their personal physicians. The investigators do not provide, prescribe, or assign any medication. Participants will use various formulations (such as CBD-dominant, THC-dominant, or balanced full-spectrum oils) administered according to their specific medical guidance. Data collection will focus on the natural course of the treatment, monitoring clinical evolution, quality of life, and safety through validated scales over a 6-month period.
Also known as: Cannabis-based products, Phytocannabinoids, CBD oil, medical marijuana, Full-spectrum
Change in Quality of Life Scores
Evaluation of the patient's quality of life using the WHOQOL-Bref questionnaire (World Health Organization Quality of Life). This scale evaluates physical, psychological, social relationships, and environment domains. Scores range from 0 to 100, where higher scores indicate a better quality of life.
Time frame: Baseline, 45 days, 75 days, 105 days, 135 days, and 180 days.
Change in Pain Intensity
Assessment of pain using the Visual Analogue Scale (VAS). Patients report their pain level on a scale from 0 (no pain) to 10 (worst possible pain).
Time frame: Baseline, 45 days, 75 days, 105 days, 135 days, and 180 days.
Change in Depression Severity
Measured by the Beck Depression Inventory (BDI). It consists of 21 items. Total scores range from 0 to 63, with higher scores indicating increased severity of depressive symptoms.
Time frame: Baseline, 45 days, 75 days, 105 days, 135 days, and 180 days.
Change in Anxiety Severity
Measured by the Beck Anxiety Inventory (BAI). It consists of 21 items. Total scores range from 0 to 63, with higher scores indicating more severe anxiety symptoms.
Time frame: Baseline, 45 days, 75 days, 105 days, 135 days, and 180 days.
Incidence of Treatment-Emergent Adverse Events
Evaluation of side effects using the UKU Side Effect Rating Scale. This scale monitors psychic, neurological, autonomic, and other side effects. It will be used to document the safety profile of the cannabinoid products.
Time frame: From Day 45 through Month 6.
Plan to share: Yes — Individual participant data (IPD) collected during the study will be shared in a de-identified format. Data access will be granted to researchers whose proposed use of the data has been formally approved by an independent review committee. The sharing process strictly complies with the Brazilian General Data Protection Law (LGPD). De-identified raw data concerning quality of life scores obtained through WHOQOL-Bref and EUROQOL-5D instruments. Clinical evolution scores for pain (Visual Analogue Scale - VAS), anxiety (Beck Anxiety Inventory - BAI), and depression (Beck Depression Inventory - BDI). Reported adverse events collected via the UKU Side Effect Rating Scale.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be available starting 6 months after the publication of the final study results. Data availability will end 36 months after publication.
Access criteria: Data will be shared through a secure file transfer or via the Zenodo repository using the de-identification standards already planned to ensure participant confidentiality.
Started Mar 2026 (actual). Primary completion is estimated for Sep 2026, 6 months after the start.
Of 337 non-industry observational studies under Chronic Pain, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 56. This study's planned 6 months is below that.
Counting every sponsor, half of 363 studies reached it within 24 months; a quarter within 12 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Santa Catarina Federal University